Anzeige
Mehr »
Login
Freitag, 01.03.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
InnoCan Pharma: Jetzt der Ausbruch aus dem Faultierkäfig?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7EA | ISIN: US92337F1075 | Ticker-Symbol: 12V
Tradegate
29.02.24
21:24 Uhr
21,800 Euro
-0,200
-0,91 %
1-Jahres-Chart
VERACYTE INC Chart 1 Jahr
5-Tage-Chart
VERACYTE INC 5-Tage-Chart
RealtimeGeldBriefZeit
21,40022,00029.02.
21,60022,00029.02.

Aktuelle News zur VERACYTE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoVERACYTE, INC. - 8-K, Current Report1
DoVERACYTE, INC. - S-8, Securities to be offered to employees in employee benefit plans1
DoVERACYTE, INC. - 10-K, Annual Report1
23.02.Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands2
23.02.Earnings call: Veracyte reports record-breaking Q4 in light of 22% revenue surge2
22.02.Recap: Veracyte Q4 Earnings2
22.02.VERACYTE, INC. - 8-K, Current Report2
22.02.Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results270SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023. "We closed 2023 with...
► Artikel lesen
06.02.Veracyte acquires C2i Genomics to enhance cancer diagnostics-
06.02.VERACYTE, INC. - 8-K, Current Report-
06.02.Veracyte Completes Acquisition of C2i Genomics227SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding...
► Artikel lesen
09.01.JPM24: Veracyte inks $95M deal to buy fellow cancer testing company C2i Genomics2
08.01.Veracyte Acquires C2i Genomics2
08.01.Cancer care startup C2i Genomics acquired by Veracyte for up to $95 million4
08.01.Veracyte Q4 revenue to grow by 18%-20% Y/Y2
08.01.Veracyte to buy Israeli cancer detection co C2i Genomics3
08.01.VERACYTE, INC. - 8-K, Current Report2
08.01.Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform151SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary unaudited financial results for the fourth quarter...
► Artikel lesen
29.11.23Veracyte's Percepta Nasal Swab Test To Assess Lung Cancer Risk With Accuracy3
22.11.23Veracyte Climbs on Conference Plans1
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1